A Disease-Oriented Team (DOT) is a multidisciplinary group of clinical, basic and translational researchers who collaborate around a specific anatomic cancer area to further the translation of Cancer Center discoveries (e.g. new targets, biomarkers, drugs, biological agents, diagnostic and therapeutic devices) through the pipeline towards interventional clinical trials. Because of their collective expertise, DOTs steward the Cancer Center's clinical research efforts, managing the clinical trials portfolio around the following principles: scientific merit, soundness of trial design, accrual potential, and likelihood for correlative translational science.
All clinical studies in cancer must undergo a feasibility review by the corresponding DOT or Tumor Board. To submit a study for review, download and complete the application and email to CancerCenter_Committees@health.uci.edu.
For meeting times and locations, please see the administrative contacts listed below.